Cited in:


This article has been cited by:

  1. 1
    J. T. Stahmeyer, C. Krauth, F. Bert, H. Pfeiffer-Vornkahl, U. Alshuth, D. Hüppe, S. Mauss, S. Rossol, Costs and outcomes of treating chronic hepatitis C patients in routine care – results from a nationwide multicenter trial, Journal of Viral Hepatitis, 2016, 23, 2
  2. 2
    S. Akamatsu, C. N. Hayes, M. Tsuge, E. Murakami, N. Hiraga, H. Abe, D. Miki, M. Imamura, H. Ochi, K. Chayama, Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, Journal of Viral Hepatitis, 2015, 22, 2
  3. 3
    Pierre Pradat, Victor Virlogeux, Marie-Claude Gagnieu, Fabien Zoulim, François Bailly, Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring, Advances in Hepatology, 2014, 2014, 1


  4. You have free access to this content4
    B. Maasoumy, K. Port, B. Calle Serrano, A. A. Markova, L. Sollik, M. P. Manns, M. Cornberg, H. Wedemeyer, The clinical significance of drug–drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2013, 38, 11-12